Hong Kong Stock Market Movement | Gilead Sciences-B(01672) rose nearly 8% in the afternoon. Gilead's first oral insulin peptide ASC36 enters clinical development.

2026-02-20 07:10:20

GigaMedia Financial APP has learned that GeneLly Pharmaceuticals-B (01672) rose nearly 8% in the afternoon. As of the time of writing, it increased by 6.75%, trading at HKD 17.72, with a turnover of HKD 36.7989 million.

In terms of news, GeneLly Pharmaceuticals recently announced that its board of directors has approved the clinical development of its first oral peptide, ASC36, an insulin receptor agonist. GeneLly expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the clinical trial of the ASC36 oral tablet for obesity treatment in the second quarter of 2026.

This marks another step for GeneLly in the field of metabolic diseases, following the ASC30 oral small molecule GLP-1 receptor agonist, with a potential to be a globally leading innovative drug. It also signifies that its proprietary oral peptide delivery enhancement technology has completed the transition from platform capability to the key value realization of a candidate drug. ASC36 is a peptide insulin receptor agonist independently developed using GeneLly’s structure-based AI-assisted drug discovery (AISBDD) technology.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.